ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (...
June 07 2019 - 7:00AM
Business Wire
Presentation highlights phase 1 dose escalation
study in patients with relapsed or refractory B-cell lymphoid
malignancies
Conference call and webcast with ArQule
management and Dr. Jennifer Woyach, Principal Investigator, to be
held Friday, June 14, 2018 at 8:00 a.m. EDT
ArQule Management to hold an Investor Event
from 5:30-8:00 p.m. CEST on June 14 in Amsterdam
ArQule, Inc. (Nasdaq: ARQL), today announced that it will
present clinical data from the company-sponsored phase 1 dose
escalation study on its BTK inhibitor, ARQ 531, for the treatment
of relapsed or refractory B-cell lymphoid malignancies in a poster
presentation at the 24th Congress of European Hematology
Association (EHA), held from June 13-16, 2019 in Amsterdam.
Presentation Details
Title: A Phase 1 Dose Escalation Study Of ARQ 531 In
Patients with Relapsed or Refractory B-Cell Lymphoid
MalignanciesAbstract #: PS1150Session: 6. Chronic
lymphocytic leukemia and related disorders - ClinicalDate:
Saturday, June 15, 2019Time: 5:30-7:00 p.m.
CESTLocation: RAI Amsterdam; Poster area
ArQule will host a conference call and webcast for investors on
Friday, June 14, 2019 at 8:00 a.m. EDT to discuss the ARQ 531
clinical data. The live webcast can be accessed in the “Investors
and Media” section of our website, www.arqule.com, under
“Events & Presentations” or by visiting
http://public.viavid.com/index.php?id=134824. You may also listen
to the call by dialing 1-800-239-9838 within the U.S. or
1-323-794-2551 outside the U.S. and providing conference ID
3110780. A replay will be available two hours after the completion
of the call and can be accessed in the “Investors & Media”
section of our website, www.arqule.com, under “Events and
Presentations.”
ArQule Management will also be hosting an Investor event to
answer questions and discuss these data on Friday, June 14th from
5:30 – 8:00 p.m. CEST. Investors, sell side analysts and industry
representatives are welcome to attend. To register to attend,
please click on the link here.
About BTK and ARQ 531Bruton’s tyrosine kinase, BTK, is a
therapeutic target that has been clinically proven to inhibit
B-cell receptor signaling in blood cancers. ARQ 531 is an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK. The C481S-mutation is a known resistance
mechanism for first generation irreversible BTK inhibitors. ARQ 531
has demonstrated a good safety profile, predictable PK, profound
pharmacodynamic effects and emerging signs of dose-proportional
clinical activity in phase 1 clinical testing.
About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop
and commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, planned to initiate registrational trial
cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in
combination with the hormonal therapy, anastrozole, in patients
with advanced endometrial cancer; ARQ 751, a next generation highly
potent and selective AKT inhibitor, in phase 1 for patients with
AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in a registrational trial for iCCA in
collaboration with Basilea and Sinovant. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190607005029/en/
Corporate Contact:Kathleen FarrenInvestor Relations&
Executive Assistant to the CFOir@arqule.com
Media Contact:Cait Williamson, Ph.D.LifeSci Public
Relations(646) 751-4366cait@lifescipublicrelations.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024